12. MARKETABLE SECURITIES - AVAILABLE-FOR-SALE

12 Months Ended

Dec. 31, 2015

Investments, Debt and Equity Securities [Abstract]

12. MARKETABLE SECURITIES - AVAILABLE-FOR-SALE

In May 2012, the Company acquired 2,052 shares of Facebook stock (FB) for $95,256 plus fees. The value of the shares at December 31, 2015 and 2014 amounted to $104,660 and  $78,020, respectively.   A 2012 decrease, gave rise to an unrealized loss of $40,632 for the year ended December 31, 2012, and then an unrealized gain of $23,371 in 2014, and an unrealized gain of $26,640 in 2015. The Company evaluated the prospects of it’s investments in relation to the severity and duration of the impairment. Based on that evaluation, the Company consider the shares to be other than temporarily impaired at December 31, 2012, and recorded loss on marketable securities in the statement of operations of $40,632.

In May 2013, the Company sold 1,052 shares of FB for $28,562, giving rise to a realized gain of $557, recorded in the statement of operations for the period ended December 31, 2013. All unrealized gains in 2014 and 2015 have been recorded as an increase to the marketable securities and an increase to accumulated other comprehensive income in equity. During 2015 the Company acquired 6,750 shares of Immune Therapeutics common stock for $1,931. As of December 31, 2015 the value was $1,484, with unrealized losses of $447 recorded as a decrease to marketable securities and accumulated other comprehensive income.